Md. biotech delivers doses of anthrax vaccine to HHS
http://washington.bizjournals.com/washington/stories/2006/12/11/daily50.html
Washington Business Journal, by Neil Adler, Staff Reporter
Emergent BioSolutions, which sells the only vaccine to protect against anthrax that is licensed by the Food and Drug Administration, says it has completed the delivery of more than 3 million doses of the vaccine to the Department of Health and Human Services.
The roughly 3 million doses, representing revenue of about $75 million to the company, are part of a $120 million contract awarded in May of this year by HHS to Gaithersburg-based Emergent for 5 million doses, to be delivered by May 31, 2007, that will go into the country's strategic national stockpile.
Under this contract, Emergent has delivered about 4 million doses and expects to supply the balance during the first quarter of next year, the company says.
In total, Emergent now has supplied more than 9 million doses of the vaccine, called BioThrax, to HHS. The company won a $123 million contract in May 2005 to supply an initial 5 million doses.
Emergent (NYSE: EBS), which recently went public with its stock, is competing with a handful of biotech and pharmaceutical companies developing anthrax drugs and vaccines for the U.S. government. These competitors include Rockville-based Human Genome Sciences (NASDAQ: HGSI).
Washington Business Journal, by Neil Adler, Staff Reporter
Emergent BioSolutions, which sells the only vaccine to protect against anthrax that is licensed by the Food and Drug Administration, says it has completed the delivery of more than 3 million doses of the vaccine to the Department of Health and Human Services.
The roughly 3 million doses, representing revenue of about $75 million to the company, are part of a $120 million contract awarded in May of this year by HHS to Gaithersburg-based Emergent for 5 million doses, to be delivered by May 31, 2007, that will go into the country's strategic national stockpile.
Under this contract, Emergent has delivered about 4 million doses and expects to supply the balance during the first quarter of next year, the company says.
In total, Emergent now has supplied more than 9 million doses of the vaccine, called BioThrax, to HHS. The company won a $123 million contract in May 2005 to supply an initial 5 million doses.
Emergent (NYSE: EBS), which recently went public with its stock, is competing with a handful of biotech and pharmaceutical companies developing anthrax drugs and vaccines for the U.S. government. These competitors include Rockville-based Human Genome Sciences (NASDAQ: HGSI).
